Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 282

1.

Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.

Andrade-Campos M, Murillo-Flórez I, García-Sanz R, Giraldo P.

Clin Chem Lab Med. 2017 Mar 11. pii: /j/cclm.ahead-of-print/cclm-2016-0748/cclm-2016-0748.xml. doi: 10.1515/cclm-2016-0748. [Epub ahead of print]

PMID:
28284031
2.

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CE.

Blood Cells Mol Dis. 2016 Oct 24. pii: S1079-9796(16)30191-7. doi: 10.1016/j.bcmd.2016.10.008. [Epub ahead of print]

PMID:
28274788
3.

Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.

García-Marco JA, Delgado J, Hernández-Rivas JA, Ramírez Payer Á, Loscertales Pueyo J, Jarque I, Abrisqueta P, Giraldo P, Martínez R, Yáñez L, Terol MJ, González M, Bosch F; en nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC)..

Med Clin (Barc). 2017 Feb 21. pii: S0025-7753(17)30033-7. doi: 10.1016/j.medcli.2016.12.030. [Epub ahead of print] English, Spanish.

PMID:
28236475
4.

Inhibition of Intermediate-Conductance Calcium-Activated K Channel (KCa3.1) and Fibroblast Mitogenesis by α-Linolenic Acid and Alterations of Channel Expression in the Lysosomal Storage Disorders, Fabry Disease, and Niemann Pick C.

Oliván-Viguera A, Lozano-Gerona J, López de Frutos L, Cebolla JJ, Irún P, Abarca-Lachen E, García-Malinis AJ, García-Otín ÁL, Gilaberte Y, Giraldo P, Köhler R.

Front Physiol. 2017 Jan 31;8:39. doi: 10.3389/fphys.2017.00039.

5.

A Novel Emergency Department-based Community Notification Method for Clinical Research Without Consent.

O'Malley GF, Giraldo P, Deitch K, Aguilera EA, Cadar S, Lares C, O'Malley RN, Oqroshidze N, Verma M, Chudnofsky C.

Acad Emerg Med. 2017 Feb 7. doi: 10.1111/acem.13173. [Epub ahead of print]

PMID:
28170159
6.

Standard hormone therapy is inadequate for bone density in premature ovarian insufficiency.

Giraldo H, Benetti-Pinto C, Ferreira V, Garmes H, Yela D, Giraldo P.

Gynecol Endocrinol. 2016 Dec 2:1-4. doi: 10.1080/09513590.2016.1257602. [Epub ahead of print]

PMID:
27910707
7.

InverPep: A database of invertebrate antimicrobial peptides.

Gómez EA, Giraldo P, Orduz S.

J Glob Antimicrob Resist. 2016 Nov 19;8:13-17. doi: 10.1016/j.jgar.2016.10.003. [Epub ahead of print]

PMID:
27888793
8.
9.

Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.

Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, Petakov M, Tan ES, Chertkoff R.

Blood Cells Mol Dis. 2016 Oct 20. pii: S1079-9796(16)30221-2. doi: 10.1016/j.bcmd.2016.10.005. [Epub ahead of print]

10.

Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.

Giraldo P, Andrade-Campos M, Alfonso P, Irun P, Atutxa K, Acedo A, Barez A, Blanes M, Diaz-Morant V, Fernández-Galán MA, Franco R, Gil-Cortes C, Giner V, Ibañez A, Latre P, Loyola I, Luño E, Hernández-Martin R, Medrano-Engay B, Puerta J, Roig I, de la Serna J, Salamero O, Villalón L, Pocovi M.

Blood Cells Mol Dis. 2016 Oct 24. pii: S1079-9796(16)30133-4. doi: 10.1016/j.bcmd.2016.10.017. [Epub ahead of print]

PMID:
27836529
11.

The utility of magnetic resonance imaging for bone involvement in Gaucher disease. Assessing more than bone crises.

Andrade-Campos M, Valero E, Roca M, Giraldo P; Spanish group on Gaucher Disease..

Blood Cells Mol Dis. 2016 Oct 21. pii: S1079-9796(16)30219-4. doi: 10.1016/j.bcmd.2016.10.004. [Epub ahead of print]

PMID:
27836527
12.

Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.

Deegan P, Fernandez-Sasso D, Giraldo P, Lau H, Panahloo Z, Zimran A.

Blood Cells Mol Dis. 2016 Oct 20. pii: S1079-9796(16)30213-3. doi: 10.1016/j.bcmd.2016.10.014. [Epub ahead of print]

13.

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.

Pleat R, Cox TM, Burrow TA, Giraldo P, Goker-Alpan O, Rosenbloom BE, Croal LR, Underhill LH, Gaemers SJ, Peterschmitt MJ.

Mol Genet Metab Rep. 2016 Sep 30;9:25-28.

14.

Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.

Elstein D, Burrow TA, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee HM, Mellgard B, Zimran A.

Mol Genet Metab. 2017 Jan - Feb;120(1-2):111-115. doi: 10.1016/j.ymgme.2016.08.005.

15.

Eleven-year descriptive analysis of closed court verdicts on medical errors in Spain and Massachusetts.

Giraldo P, Sato L, Martínez-Sánchez JM, Comas M, Dwyer K, Sala M, Castells X.

BMJ Open. 2016 Aug 30;6(8):e011644. doi: 10.1136/bmjopen-2016-011644.

16.

Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.

Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau C, Plӧckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM.

Eur J Intern Med. 2017 Jan;37:25-32. doi: 10.1016/j.ejim.2016.07.011. Review.

17.

Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R.

N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198.

18.

Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.

Zimran A, Durán G, Giraldo P, Rosenbaum H, Giona F, Petakov M, Terreros Muñoz E, Solorio-Meza SE, Cooper PA, Varughese S, Alon S, Chertkoff R.

Blood Cells Mol Dis. 2016 Jul 18. pii: S1079-9796(16)30087-0. doi: 10.1016/j.bcmd.2016.07.002. [Epub ahead of print]

19.

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Arguiñano JM, Quintana N, García JL, Bladé J, Lahuerta JJ, Miguel JF.

Lancet Oncol. 2016 Aug;17(8):1127-36. doi: 10.1016/S1470-2045(16)30124-3.

PMID:
27402145
20.

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.

Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM.

Haematologica. 2016 Sep;101(9):1065-73. doi: 10.3324/haematol.2016.143677.

Supplemental Content

Loading ...
Support Center